Literature DB >> 33495216

Reply to Béranger et al., "Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children".

Jumpei Saito1, Kensuke Shoji2, Yusuke Oho3, Hiroki Kato4, Shotaro Matsumoto4, Satoshi Aoki4, Hidefumi Nakamura5, Takanori Ogawa6, Mayumi Hasegawa6, Akimasa Yamatani3, Isao Miyairi2,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33495216      PMCID： PMC8097448          DOI： 10.1128/AAC.02592-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

Review 1.  Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.

Authors:  Matteo Di Nardo; Enno Diederick Wildschut
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample.

Authors:  Andreas S L Mendez; Jean Dalomo; Martin Steppe; Elfrides E S Schapoval
Journal:  J Pharm Biomed Anal       Date:  2006-03-14       Impact factor: 3.935

3.  Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children.

Authors:  Agathe Béranger; Naïm Bouazza; Mehdi Oualha
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  Investigation of Key Circuit Constituents Affecting Drug Sequestration During Extracorporeal Membrane Oxygenation Treatment.

Authors:  Jiheum Park; Dong Ah Shin; Saram Lee; Young-Jae Cho; Sanghoon Jheon; Jung Chan Lee; Hee Chan Kim
Journal:  ASAIO J       Date:  2017 May/Jun       Impact factor: 2.872

5.  Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion.

Authors:  Sarah Fawaz; Stephen Barton; Laura Whitney; Julian Swinden; Shereen Nabhani-Gebara
Journal:  Hosp Pharm       Date:  2018-05-30

6.  Antimicrobial Disposition During Pediatric Continuous Renal Replacement Therapy Using an Ex Vivo Model.

Authors:  Prashant J Purohit; Mohammed H Elkomy; Adam Frymoyer; Scott M Sutherland; David R Drover; Gregory B Hammer; Felice Su
Journal:  Crit Care Med       Date:  2019-09       Impact factor: 7.598

7.  Determinants of drug absorption in different ECMO circuits.

Authors:  E D Wildschut; M J Ahsman; K Allegaert; R A A Mathot; D Tibboel
Journal:  Intensive Care Med       Date:  2010-09-23       Impact factor: 17.440

8.  Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients.

Authors:  Jumpei Saito; Kensuke Shoji; Yusuke Oho; Hiroki Kato; Shotaro Matsumoto; Satoshi Aoki; Hidefumi Nakamura; Takanori Ogawa; Mayumi Hasegawa; Akimasa Yamatani; Isao Miyairi
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

9.  Population pharmacokinetics of meropenem in critically ill children with different renal functions.

Authors:  Mélanie Rapp; Saïk Urien; Frantz Foissac; Agathe Béranger; Naïm Bouazza; Sihem Benaboud; Emmanuelle Bille; Yi Zheng; Inès Gana; Florence Moulin; Fabrice Lesage; Sylvain Renolleau; Jean Marc Tréluyer; Déborah Hirt; Mehdi Oualha
Journal:  Eur J Clin Pharmacol       Date:  2019-10-26       Impact factor: 2.953

10.  Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam.

Authors:  Fekade B Sime; Saurabh Pandey; Nermin Karamujic; Suzanne Parker; Elizabeth Alexander; Jeffery Loutit; Stephanie Durso; David Griffith; Jeffrey Lipman; Steven C Wallis; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.